Yakup Ergün· @dr_yakupergun · X·· 2 days agoScore90
Body
#ESMO26 | NATALEE – 6-year results (Pre-presentation abstract)
6-year OS: 92.73% vs 89.38% (HR 0.809; nominal p=0.019).
iDFS: HR 0.741; absolute benefit of 4.1% at 6 years.
In monarchE, a 7-year OS benefit was demonstrated (HR 0.842; p=0.027).
NATALEE also shows a promising OS signal; however, formal statistical significance has not yet been established.
Looking forward to the presentation....
5093 views · 17 likes · 4 reposts · 0 replies
Conference abstracts
LBA25matched by Proffered paper 1: Breast cancer, early and advanced stage
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.orgSource: Yakup Ergün · x.com